On December 8, 2022 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, reported the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50 per share (Press release, Replimune, DEC 9, 2022, View Source [SID1234624958]). In addition, in lieu of common stock to certain investors, Replimune reported the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $225 million, before deducting the underwriting discounts and commissions and offering expenses payable by Replimune. All securities in the offering are being offered by Replimune. In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Securities LLC, SVB Securities LLC, Piper Sandler and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.

A preliminary prospectus supplement relating to and describing the terms of the offering were filed with the Securities and Exchange Commission (the "SEC") on December 7, 2022. The final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by e-mail at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at [email protected]; Piper Sandler, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at [email protected]; BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, by telephone at (800) 414-3627, or by email at [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

The securities described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Replimune with the SEC on June 23, 2022 and declared effective by the SEC on July 27, 2022. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On December 8, 2022 iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, reported the first patient has been dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer (Press release, iOnctura, DEC 8, 2022, View Source [SID1234640235]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to progress clinical development of our autotaxin (ATX) inhibitor IOA-289, the second most advanced product in our pipeline," said Catherine Pickering, PhD, CEO of iOnctura. "Our preclinical research has uncovered a central role for ATX as a tumor survival factor, especially in highly fibrotic malignancies such as pancreatic, liver, colorectal, ovarian and breast cancers. To our knowledge, this is the first time an ATX inhibitor will be investigated in cancer patients. The learnings from this study will serve as a prototype to explore the therapeutic potential of IOA-289 in further fibrotic cancers."

The Phase Ib AION-02 study (NCT05586516) is a dose-escalation study of IOA-289 in combination with standard-of-care gemcitabine/nab-paclitaxel chemotherapy in first-line metastatic pancreatic cancer. Patients will be dosed with IOA-289 monotherapy for 7 days before commencing combination treatment of IOA-289 and chemotherapy.

Fibrotic cancers, including pancreatic cancer, are characterized by the deposition of thick layers of extracellular matrix containing collagen fibers and pro-tumorigenic factors. This microenvironment impedes the entry of immune cells and drugs, making the tumors difficult to treat.

"IOA-289 is an orally dosed small molecule that has been shown preclinically to have a multi-pronged approach to treating cancer, acting directly to prevent proliferation of tumor cells and indirectly to potentiate the actions of the immune system and chemotherapy in the fibrotic microenvironment." said David Brindley, Professor of Biochemistry, University of Alberta, and member of iOnctura’s clinical advisory board. "We hypothesize that the lead-in of IOA-289 will reduce the expression of collagen and other pro-tumorigenic secreted factors rendering the tumor microenvironment susceptible to chemotherapy and unveiling the tumor to the immune system."

The trial’s primary endpoint is to evaluate the safety and tolerability of the ascending doses of IOA-289. Secondary endpoints include biomarker changes and efficacy endpoints. The trial will be conducted in sites in Italy and the UK. The principal investigators of the trial are Professor Davide Melisi, University of Verona, Professor Michele Maio, University of Siena and Professor Jeff Evans, University of Glasgow.

IOA-289 is the first autotaxin (ATX) inhibitor in clinical development for cancer. It is an oral small molecule non-competitive inhibitor with novel binding chemistry and a safe clinical profile. It has been shown that inhibiting ATX with IOA-289 directly prevents the proliferation of cancer cells1. Furthermore, IOA-289 interrupts resistance to cancer therapy by reducing fibrotic scar tissue, unveiling the tumor and enabling the immune system to recruit infiltrating lymphocytes into the tumor2. Thanks to this multi-pronged mode of attack, IOA-289 reduced tumor burden in mouse pancreatic cancer models1.

Pancreatic cancer (PDAC): Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer accounting for approximately 90% of cases. PDAC has a poor prognosis, with less than 5% of patients surviving beyond five years after diagnosis. There are over 50,000 diagnoses of pancreatic cancer each year in the United States and over 65,000 in the EU5.

On December 8, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that Blackstone Life Sciences (‘Blackstone’) has committed to make two pre-agreed milestone payments of $35m each to Autolus, totaling $70m (Press release, Autolus, DEC 8, 2022, View Source [SID1234625453]). The milestones are expected to be recognized in Autolus’ Q4 2022 cash balance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first Blackstone milestone of $35m is being paid earlier than anticipated as a result of the joint steering committee’s review of Autolus’ interim analysis of pivotal FELIX Phase 2 clinical trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL). The study has met its primary endpoint, the details of which have been announced in a separate press release today.

The second Blackstone milestone of $35m is a pre-agreed manufacturing milestone as a result of completion of planned activities demonstrating the performance and qualification of Autolus’ obe-cel’s manufacturing process.

"Receiving these two $35m milestone payments highlights the continuing strength and collaborative nature of our partnership with Blackstone," said Dr. Christian Itin, CEO of Autolus. "We are delighted to have demonstrated the potential merits of obe-cel’s clinical profile and our evolving robust manufacturing process to the Blackstone team, and look forward to continued progress together as we focus on our goal of submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the end of 2023."

"We are pleased with Autolus’ progress —we continue to believe obe-cel has the potential to become a transformative therapy for relapsed/refractory adult ALL patients," said Nicholas Simon, Senior Managing Director with Blackstone Life Sciences. "Our investments in these next generation cell therapies with Autolus exemplifies our conviction in the quality and promise of the life sciences sector in the UK."

As previously announced, Autolus and Blackstone entered into a strategic collaboration and financing agreement in November 2021, whereby funds managed by Blackstone agreed to provide up to $250 million in equity and product financing to support Autolus’ advancement of obe-cel, its CD19 CAR T cell investigational therapy product candidate, as well as next generation product candidates of obe-cel in B-cell malignancies.

On December 8, 2022 Eigen Therapeutics, the biotech startup on a mission to make cancer easier to find and eliminate, reported their launch today (Press release, Eigen Therapeutics, DEC 8, 2022, View Source [SID1234624978]). They also announced a $7 million seed round led by Josh Kopelman at First Round Capital, with participation from Builders VC, Kevin Mahaffey, Hawktail, Matthew De Silva (founder at Notable Labs), Varsha Rao, Bioverge, Alumni Ventures, Mount Pleasant Ventures, and others.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eigen was founded by an engineer and a scientist, Transon Nguyen and Kamran Ali, who have assembled a diverse team of experts in technology and biological sciences. Both founders are veterans of Notable Labs, where they gained deep experience in the cancer drug discovery industry, and where they began to grapple with the gaps in targeted therapy success rates.

"Targeted therapies, including antibody-drug conjugates and CAR T-cell therapies, are incredibly effective in some instances and have significantly moved cancer treatment forward," explains Eigen CEO Transon Nguyen. "But they could be far more effective than they are today. There’s a lot of focus on developing better, smarter targeted therapies, but we noticed there hasn’t been much attention on the other side of the equation. So we asked: What if we also made cancer cells easier for targeted therapies to eliminate?"

Eigen focuses on priming therapies that make cancer cells more visible—so they can be identified faster. The company takes a two-step approach to treating cancer. The first step is a priming therapy, which essentially shines a spotlight on the cancer cells to make them more recognizable. They do this by increasing target expression across cancer cells.

"Once the cancer has been primed and highlighted, the targeted therapeutic can more easily find and attack the tumor cells and eliminate the cancer," says Eigen CTO Kamran Ali. "When priming therapies are paired with targeted therapies, cancer treatment can become far more effective."

Eigen will use the capital from their seed round to apply their novel high-throughput platform toward the development of priming therapies. Their initial programs are focused on hematological malignancies; in the future, their platform will allow them to quickly spin up programs for other cancer indications, such as solid tumors.

For Nguyen and Ali, the platform-based approach is a logical choice, as Notable was one of the first companies to prove out the thesis that a full-stack approach integrating robotics, software, and biology is a viable strategy for scaling up cancer drug discovery. Transon was Notable’s founding engineer, Head of Laboratory Automation, and VP of Engineering; Kamran was Notable’s Head of Platform and Discovery.

"Priming therapies have the potential to improve targeted therapies, and ultimately, the lives of cancer patients," says Josh Kopelman, founding partner at First Round Capital. "However, it’s a widely unsearched field. Eigen’s team and the platform they’ve built are the perfect match to systematically search this field and develop more priming therapies."

Eigen’s high-throughput platform takes a combinatorial functional screening approach to exploring the space of priming therapies. It uses proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell’s state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.

On December 8, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, reported preclinical data demonstrating that STX-478, the Company’s highly differentiated, allosteric and central nervous-system ("CNS") penetrant inhibitor of mutant phosphoinositide-3-kinase alpha ("PI3Kα"), has a potentially best-in-class product profile, with the ability to improve outcomes in patients harboring tumors with prevalent PI3Kα kinase or helical domain mutations (Press release, Scorpion Therapeutics, DEC 8, 2022, View Source [SID1234624977]). The data is being presented for the first time today in a poster session at the San Antonio Breast Cancer Symposium ("SABCS") in San Antonio, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to share new preclinical data on STX-478 that further demonstrates its potential best-in-class product profile and supports its advancement into first-in-human clinical trials," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. "In these studies, STX-478 showed robust anti-tumor activity as both a monotherapy and in combination with standard of care agents in models with kinase or helical domain mutations. Importantly, this activity was coupled with key features that differentiate STX-478 from other PI3Kα inhibitors. STX-478 exhibited high mutant selectivity, without the dose-limiting metabolic dysfunction associated with currently available treatments. It also displayed an ability to reach the CNS, which could address the brain metastases that often occur in patients with solid tumors, but are poorly treated by existing options. We look forward to filing our IND application in the first quarter of 2023 and initiating our Phase 1 study in patients soon thereafter."

PI3Kα is one of the most highly mutated targets in all of cancer. In the United States, over 166,000 patients per year present with cancers, including breast, gynecological and head and neck, which harbor PI3Kα mutations.1 Scorpion specifically designed STX-478 to deliver superior safety, tolerability and efficacy compared to currently marketed PI3Kα therapies and certain drug candidates known to be in development, while exhibiting excellent drug-life properties and a favorable therapeutic index.

In the preclinical data presented at SABCS, STX-478 demonstrated exceptional selectivity for PI3Kα, inhibiting the viability of both kinase and helical domain mutated cell lines in vitro. In addition, STX-478 demonstrated robust monotherapy activity in vivo, as well as combination activity with relevant co-treatments, across a variety of cancer types in xenograft studies. This includes a T47D ER+, HER2- breast cancer model, in which STX-478 treatment caused deep tumor regressions alone and in combination with fulvestrant; a panel of ER+ BrCa patient derived xenograft ("PDX") models, in which STX-478 was highly efficacious alone and in combination with fulvestrant or palbociclib; and an ER+ PDX model carrying a helical domain mutation, in which STX-478 inhibited tumor cell growth.

Importantly, STX-478 also demonstrated promising tolerability. Chronic dosing of STX-478 did not cause metabolic dysfunction in murine models at efficacious doses, nor did it affect blood glucose levels in higher species, even at doses that provide exposure well-above the efficacious exposure in murine models.

"We are particularly encouraged to present data for the first time showcasing STX-478’s activity against PI3Kα helical domain mutations, which could enable our investigational therapy to treat a large number of patients," said Darrin Stuart, Ph.D., Chief Scientific Officer of Scorpion. "This further showcases the demonstrated ability of our drug development platform to bring together scientific breakthroughs in biology, chemistry and data sciences to create superior product candidates that can extend the reach of precision medicine to many more people battling cancer. We look forward to initiating our first Phase 1 study of STX-478 next year."

Scorpion has completed IND-enabling studies for STX-478 and expects to file an IND application with the U.S. Food and Drug Administration in the first quarter of 2023. Scorpion anticipates evaluating STX-478 as a monotherapy and in relevant combinations with approved standard-of-care agents in patients harboring PI3Kα mutations in either the kinase or helical domain.

The poster presentation is now available here and under "Media" in the News section of Scorpion’s website: View Source Scorpion previously presented preclinical proof-of-concept data showcasing the exceptional selectivity of STX-478 for PI3Kα against the kinome, as well as pharmacokinetic analyses suggesting that STX-478 demonstrates from outstanding drug-like properties with adequate CNS exposure to treat brain tumors or metastases, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in April 2022.